EUVIMEDOdkrijte EUVIMED
Crossref

Inhibition of DNA polymerase eta‐mediated translesion DNA synthesis with small molecule sensitises ovarian cancer stem‐like cells to chemotherapy

Subhankar Bose, Priyanka Saha, Md Tanjim Alam, Bilash Chatterjee, Mrinmoy Sarkar, Amit Kumar Dixit, Deepak Kumar, Rakesh Kumar Pathak, Prem Prakash Tripathi, Amit Kumar Srivastava

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70037 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025. Written by Subhankar Bose and 9 co-authors. Institution: Cancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India. Major MEDLINE topics: Ovarian Neoplasms, DNA-Directed DNA Polymerase, Neoplastic Stem Cells, Antineoplastic Agents. Cited 2 times so far (Crossref); 62 references. Funded by: Council of Scientific and Industrial Research, India, CSIR - Indian Institute of Chemical Biology.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Background and Purpose Chemoresistance and tumour relapse pose significant challenges in achieving successful chemotherapy outcomes. Targeting DNA polymerase eta (Pol ƞ)‐mediated mutagenic translesion DNA synthesis (TLS) has emerged as a promising strategy for improving chemotherapy. However, the identification of small molecule inhibitors targeting Pol ƞ ‐ mediated TLS with high in vivo efficacy remains a challenge. Experimental Approach The small molecule was identified through in silico screening. Pol η inhibitory potential of the identified small molecule was validated by a fluorescent‐based reporter strand displacement assay. Flow cytometry was conducted to analyse the CD44 + CD117 + cancer stem‐like cell (CSC) population and live‐dead cell population. Xenograft mouse models were used to test the CSC sensitising potential. Key Results We screened and identified chrysin as a small‐molecule inhibitor that sensitises ovarian cancer stem‐like cells to cisplatin treatment by inhibiting Pol ƞ ‐mediated TLS. Chrysin effectively inhibits Pol ƞ expression, mitigates cancer stem‐like cell enrichment and enhances cisplatin‐induced cell death both in vitro and in vivo . Furthermore, chrysin treatment reduces spontaneous and cisplatin‐induced mutagenesis. Pre‐treatment with chrysin attenuates cisplatin‐induced haematological toxicity and suppresses tumour growth in human ovarian cancer xenografts. Conclusions and Implications These results establish chrysin as a novel class of TLS inhibitors and highlight its potential as a chemotherapy adjuvant for overcoming chemoresistance and improving treatment outcomes in ovarian cancer.

Subjects

MeSH terms (MEDLINE)

Ovarian NeoplasmsDNA-Directed DNA PolymeraseNeoplastic Stem CellsAntineoplastic AgentsFlavonoidsFemaleHumansAnimalsMiceCisplatinCell Line, TumorXenograft Model Antitumor AssaysMice, NudeTranslesion DNA SynthesisY-Family DNA Polymerases

Author keywords

cancer stem‐like cells (CSCs)chemoresistancechrysinmutagenesistranslesion DNA synthesis (TLS)

Substances

DNA-Directed DNA PolymeraseAntineoplastic AgentsFlavonoidsCisplatinchrysinRad30 proteinY-Family DNA Polymerases

Authors and institutions

  • Cancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Department of Biochemistry, Central Ayurveda Research Institute, Kolkata, India.
  • Organic and Medicinal Chemistry Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
  • Department of Chemical Science, Indian Institute of Science Education and Research Berhampur, Odisha, India.
  • Cell Biology and Physiology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.

Funding

  • Council of Scientific and Industrial Research, India
  • CSIR - Indian Institute of Chemical Biology

Cite

APA

Bose, S., Saha, P., Alam, M. T., Chatterjee, B., Sarkar, M., Dixit, A. K., Kumar, D., Pathak, R. K., Tripathi, P. P., & Srivastava, A. K. (2025). Inhibition of DNA polymerase eta‐mediated translesion DNA synthesis with small molecule sensitises ovarian cancer stem‐like cells to chemotherapy. British Journal of Pharmacology. https://doi.org/10.1111/bph.70037

Vancouver

Bose S, Saha P, Alam MT, Chatterjee B, Sarkar M, Dixit AK, et al. Inhibition of DNA polymerase eta‐mediated translesion DNA synthesis with small molecule sensitises ovarian cancer stem‐like cells to chemotherapy. British Journal of Pharmacology. 2025. doi:10.1111/bph.70037

BibTeX
@article{Bose2025,
  author = {Bose, Subhankar and Saha, Priyanka and Alam, Md Tanjim and Chatterjee, Bilash and Sarkar, Mrinmoy and Dixit, Amit Kumar and Kumar, Deepak and Pathak, Rakesh Kumar and Tripathi, Prem Prakash and Srivastava, Amit Kumar},
  title = {Inhibition of DNA polymerase eta‐mediated translesion DNA synthesis with small molecule sensitises ovarian cancer stem‐like cells to chemotherapy},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70037}
}
Start for free →